Trial Profile
A Phase IV, Prospective, Non-Interventional, Multicenter Study Evaluating the Efficacy and Safety of Tolvaptan in Patients with Heart Failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2019
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms SMILE
- 27 Sep 2019 Results from the subgroup (HFrEF, HFpEF, and HFmrEF) analysis from the Samsca Post- Marketing Surveillance in HF (SMILE) study investigating the safety and efficacy of tolvaptan published in the International Heart Journal
- 22 May 2019 Results published in the Circulation Journal
- 31 Mar 2018 According to results published in the Circulation Journal, the study period was from 2011 to 2016.